Compare LGIH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | OGN |
|---|---|---|
| Founded | 2003 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2013 | 2020 |
| Metric | LGIH | OGN |
|---|---|---|
| Price | $50.78 | $13.66 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $75.90 | $11.40 |
| AVG Volume (30 Days) | 222.5K | ★ 3.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.25 | 0.95 |
| Revenue | $1,705,504,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $2.32 | $0.45 |
| Revenue Next Year | $17.94 | $1.67 |
| P/E Ratio | $39.66 | ★ $14.36 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $5.69 |
| 52 Week High | $66.25 | $13.79 |
| Indicator | LGIH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 43.71 |
| Support Level | $46.17 | $13.46 |
| Resistance Level | $55.62 | $13.79 |
| Average True Range (ATR) | 1.93 | 0.03 |
| MACD | -0.68 | -0.02 |
| Stochastic Oscillator | 23.60 | 12.90 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.